CURRICULUM VITAE

XIAOQUN DONG, M.D., Ph.D.

Business or Mailing Address:	55 Claverick Street Providence, RI 02903, USA
Business Telephone No.:	401-444-4493
Business Fax No.:	401-444-2939
Cell phone:	713-670-6006
Email:	Xiaoqun_Dong@Brown.edu

EDUCATION

Institution	Degree	Year
Jiamusi University School of Medicine	M.D.	1998
Harbin Medical University	M.S.	2003
Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Tsinghua University	Ph.D.	2006

POSTGRADUATE TRAINING

Postdoctoral Fellowship:

2007-2012 Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center

POSTGRADUATE HONORS AND AWARDS

Year	Award
2008	The University of Texas MD Anderson Cancer Center: First Place for Bayer HealthCare Pharmaceuticals, Inc. Award in Population/Patient-Oriented Research for Trainee Research Day
2009	The University of Texas MD Anderson Cancer Center: Poster Finalist for Bayer HealthCare Pharmaceuticals, Inc. Award in Population/Patient-Oriented Research for Trainee Research Day
2011	The University of Texas MD Anderson Cancer Center: Poster Finalist for Bayer HealthCare Pharmaceuticals, Inc. Award in Population/Patient-Oriented Research for Trainee Research Day
2011	AACR-FNAB Fellows Grant for Translational Pancreatic Cancer Research
2011	Khalifa Bin Zayed Al Nahyan Foundation Award

ACADEMIC APPOINTMENTS

Year	Academic Title and Institution
2019.1–	Assistant Professor, Liver Research Center, Lifespan/Rhode Island Hospital; Department of Medicine, The Warren Alpert Medical School of Brown University
2018.11–	Visiting Professor, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R. China
2017.7–	Visiting Professor, Harbin Medical University, Heilongjiang Province, P.R. China
2015.1–	Visiting Professor, Shijitan Hospital, Capital Medical University; The 9th Affiliated Hospital of Peking University, Beijing, P.R. China
2014.8–2018.12	Assistant Professor (tenure-track), The University of Oklahoma Health Sciences Center

2014.2–	Adjunct Assistant Professor, Department of Medicine, Warren Alpert Medical School, Brown University
2012.3 – 2014.7	Assistant Professor (tenure-track), The University of Rhode Island
2000.9 – 2003.8	Oncologist, Cancer Hospital & Institute of Harbin Medical University, China
1998.9 – 2000.8	Resident Physician, Workers' Hospital of Harbin, Heilongjiang Province, China

PATENT

1. Provisional Application # 16108026; International Application# PCT/US18/47396: Antibody-Drug Conjugates Targeted at Human Aspartyl-(Asparaginyl)-B-Hydroxylase (HAAH). Inventors: Hossein A. Ghanbari, Jack R. Wands, Xuewei Bai, Xiaoqun Dong
2. Provisional Application: Inhibition of ASPH expressing tumor growth and progression. Inventors: Jack R. Wands, ***Xiaoqun Dong***; International Filing Date 13.12.2019; Publication Number WO/2020/123912; Publication Date 18.06.2020

EDITORIAL BOARD

Cancer Letters
American Journal of Cancer Research (AJCR)
Scientific Reports - Nature
International Journal of Molecular Sciences (Guest Editor)

SCEINTIFIC REVIEWER FOR

Molecular Therapy
Autophagy
BBA - Reviews on Cancer
Helicobacter
Cancer
Molecular Carcinogenesis
Cancer Letters
Molecular Biology Reports
PLoS ONE
Scientific Reports
Journal of the Renin-Angiotensin-Aldosterone System
The International Journal of Biochemistry & Cell Biology
Am J Nephrol.
Molecular Cancer
Clinica Chimica Acta
Cancer Gene Therapy
Oncotarget
Tumor Biology
Cancer Research
Clinical Cancer Research
Chinese Journal of Cancer Research
Chinese Clinical Oncology
Cancer Cell International
Theranostics

Gene
Pediatric Research
OncoTargets and Therapy
BMC Cancer
Ageing
Frontiers in Oncology
Life Sciences
Drug Design, Development and Therapy
American Journal of Cancer Research
Expert Opinion On Therapeutic Targets
Cells
Cancers
Science Bulletin

MEMBERSHIP IN SOCIETIES

2008 Member of American Association for Cancer Research (AACR)
2008 Member of AACR Molecular Epidemiology Working Group (MEG)
2008 Member of AACR Women in Cancer Research (WICR)
2012 Member of American Association of Colleges of Pharmacy (AACP)
2012 Member of American Gastroenterological Association (AGA)

PUBLICATION LIST

1. Bai X, Zhou Y, Yokota Y, Matsumoto Y, Zhai B, Maarouf N, Hayashi H, Carlson R, Zhang S, Sousa A, Sun B, Ghanbari H, ***Dong X****, Wands J. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. *J Exp Clin Cancer Res.* (in press)
2. Bai X, Zhou Y, Lin Q, Huang C, Zhang S, Carlson R, Ghanbari H, Sun B, Wands J, ***Dong X***. Bio-nanoparticle based therapeutic vaccine induces immunogenic response against triple negative breast cancer. *Am J Cancer Res.* 2021;11(9):4141-4174. eCollection 2021.
3. Lin Q, Meng F, Chen X, Ogawa K, Nagaoka K, Xu Q, He F, Bai X, Sun B, Hung M, Wands J, Liu L, ***Dong X***. Multi-Organ Metastasis as Destination for Breast Cancer Cells Guided by Biomechanical Architecture. *Am J Cancer Res.* 2021;11(6):2537-2567. eCollection 2021.
4. Zhang Y, Huang H, Liu W, Liu S, Wang XY, Diao ZL, Zhang AH, Guo W, Han X, ***Dong X***, Katilov O. Endothelial progenitor cells-derived exosomal microRNA-21-5p alleviates sepsis-induced acute kidney injury by inhibiting RUNX1 expression. *Cell Death Dis*. 2021;12(4):335.
5. Wang J, Wu H, Zhou Y, Pang H, Liu Y, Oganezov G, Lv T, Li J, Xu J, Xiao Z, ***Dong X***. HIF-1α inhibits mitochondria-mediated apoptosis and improves the survival of human adipose-derived stem cells in ischemic microenvironments. *J Plast Reconstr Aesthet Surg.* 2021;74(8):1908-1918.
6. Ogawa K, Lin Q*, Li L, Bai X, Chen X, Li M, Xu Q, He F, Zhang S, Nagaoka K, Safran H, Charpentier K, Liu L, Sun B, Wands J, ***Dong X***. Prometastatic Secretome Trafficking via Exosomes Initiates Pancreatic Cancer Pulmonary Metastasis. *Cancer Lett*. 2020;481:63-75.
7. Lin Q, Chen X, Meng F, Ogawa K, Li M, Xu Q, He F, Bai X, Sun B, Hung M, Liu L, Wands J, ***Dong X***. ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis. *Molecular Cancer.* 2019;18(1):156.
8. Ogawa K, Lin Q*, Li L, Bai X, Chen X, Li M, Xu Q, He F, Zhang S, Nagaoka K, Safran H, Charpentier K, Liu L, Sun B, Wands J, ***Dong X***. Aspartate β-hydroxylase promotes pancreatic

ductal adenocarcinoma metastasis through activation of SRC signaling pathway. *J Hematol Oncol.* 2019;12(1):144.

9. Nagaoka K, Bai X, Ogawa K, ***Dong X***, Zhang S, Zhou Y, Carlson R, Jiang Z, Steve F, Lebowitz M, Ghanbari H, Wands J. Anti-tumor activity of antibody drug conjugate targeting aspartate-b-hydroxylase in pancreatic ductal adenocarcinoma. *Cancer Lett*. 2019;449:87-98.
10. Wang J, Wu H, Xiao Z, ***Dong X***. Expression Profiles of lncRNAs and circRNAs in Keloid. *Plast Reconstr Surg Glob Open.* 2019;7(6):e2265.
11. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin. Han B, Huang J, Han Y, Hao J, Wu X, Song H, Chen X, Shen Q, ***Dong X***, Pang H, Cai L. *Int J Biol Macromol.* 2019;125:544-556.
12. Zhao H, Yue Z, Wang L, Fan Z, He F, ***Dong X***, Liu F. Benefits of early treatment for patients with hepatic myelopathy secondary to TIPS: a retrospective study in Northern China. *Sci Rep.* 2018; 8:15184.
13. Han J, Han B, Wu X, Hao J, ***Dong X***, Shen Q, Pang H. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. *Toxicol Appl Pharmacol.* 2018;359:55-61.
14. Li H, Yue Z, Zhao H, Wang L, Fan Z, He F, ***Dong X***, Liu F. Pathological Features of Mitochondrial Ultrastructure Predict Susceptibility to Post-TIPS Hepatic Encephalopathy. *Can J Gastroenterol Hepatol.* 2018;2018:4671590.
15. Wu H, Wang J, Ma H, Xiao Z, ***Dong X***. MicroRNA-21 inhibits mitochondria-mediated apoptosis in keloid. *Oncotarget.* 2017;8(54):92914-92925.
16. Iwagami Y, Casulli S, Nagaoka K, Kim M, Carlson RI, Ogawa K, Lebowitz MS, Fuller S, Biswas B, Stewart S, ***Dong X***, Ghanbari H, Wands JR. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. *Heliyon.* 2017;3(9):e00407.
17. Wu H, Wang J, Ma H, Xiao Z, ***Dong X***. MicroRNA-21 Inhibits Apoptosis in Keloid. *Oncotarget* 2017;8(54):92914-92925.
18. Qu K, Wang Z, Li J, Liu J, Li P, Liang Z, An H, Jiang Y, Mao X, Wan Y, He F, Lin Q, ***Dong X****, Liu P, Liu C. MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma. *Cell Death Dis*. 2017;8(2):e2603.
19. Qiu B, Li K, ***Dong X***, Liu F. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. *Cardiovasc Intervent Radiol.* 2017;40(9):1372-1382.
20. Wang L, He F, Yue Z, Zhao H, Fan Z, Zhao M, Qiu B, Yao J, Lin Q, ***Dong X****, Liu F. Techniques and long-term effects of transjugular intrahepatic portosystemic shunt on liver cirrhosis-related thrombotic total occlusion of main portal vein. *Sci Rep.* 2017;7(1):10868.
21. Peng F, Hu D, Lin X, Chen G, Liang B, Zhang H, ***Dong X***, Lin J, Zheng X, Niu W. Analysis of Preoperative Metabolic Risk Factors Affecting the Prognosis of Patients with Esophageal Squamous Cell Carcinoma: The Fujian Prospective Investigation of Cancer (FIESTA) Study. *EBioMedicine.* 2017. pii: S2352-3964(17)30039-7.
22. He F, Dai S, Wang L, Yue Z, Zhao H, Fan Z, Zhao M, Yao J, Lin Q, ***Dong X****, Liu F. Transjugular intrahepatic portosystemic shunt for acute and sub-acute Budd–Chiari syndrome with diffuse occlusion of hepatic veins. *Sci Rep.* 2016;6:36380.
23. He F, Dai S, Wang L, Yue Z, Zhao H, Fan Z, Zhao M, Yao J, Lin Q, ***Dong X****, Liu F. Pathological predictors of shunt restenosis and hepatic encephalopathy after transjugular intrahepatic

portosystemic shunt. *Biomed Res Int.* 2016; 2016: 3681731.

24. Zhao M, Yue Z, Zhao H, Wang L, Fan Z, He F, Yao J, ***Dong X****, Liu F. Techniques of TIPS in the treatment of liver cirrhosis combined with incompletely occlusive main portal vein thrombosis. *Sci Rep.* 2016;6:33069.
25. Yu C, Song Z, Xiao Z, Lin Q, ***Dong X****. Mucoepidermoid carcinoma arising in Warthin's tumor of the parotid gland: Clinicopathological characteristics and immunophenotypes. *Sci Rep.* 2016;6:30149.
26. Huang CK, Iwagami Y, Aihara A, Chung W, de la Monte S, Thomas JM, Olsen M, Carlson R, Yu T, ***Dong X***, Wands J. Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression. *PLoS One.* 2016;11(3):e0150336.
27. Zhang Y, Hu J, Zhang J, Zhou X, Li X, Gu C, Liu T, Xie Y, Liu J, Gu M, Wang P, Wu T, Qian J, Wang Y, ***Dong X***, Yu J, Zhang Q. Genome-wide association study identifies multiple susceptibility loci for craniofacial microsomia. *Nat Commun.* 2016;7:10605.
28. Qu K, Lin T, Pang Q, Liu T, Wang Z, Tai M, Meng F, Zhang J, Wan Y, Mao P, ***Dong X***, Liu C, Niu W, Dong S. Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations. *Oncotarget.* 2016;7(23):33994-4010.
29. Huang H, Luo Y, Liang Y, Long X, Peng Y, Liu Z, Wen X, Jia M, Tian R, Bai C, Li C, He F, Lin Q, Wang X, ***Dong X***, CD4+CD25+ T Cells in primary malignant hypertension related kidney injury. *Sci Rep.* 2016;6:27659.
30. Iwagami Y, Huang CK, Olsen MJ, Thomas JM, Jang G, Kim M, Lin Q, Carlson RI, Wagner CE, ***Dong X***, Wands JR. Aspartate β-hydroxylase modulates cellular senescence via glycogen synthase kinase 3β in hepatocellular carcinoma. *Hepatology* 2016;63(4):1213-1226.
31. Huang H, Luo Y, Liang Y, Long X, Peng Y, Liu Z, Wen X, Jia M, Tian R, Bai C, Li C, Wang X, He F, Lin Q, ***Dong X***. CD4+CD25+ cells in multiple myeloma related renal impairment. *Sci Rep.* 2015 Nov 13;5:16565. doi: 10.1038/srep16565.
32. Chung W, Kim M, de la Monte S, Longato L, Carlson R, Slagle B, ***Dong X***, Wands J. Activation of signal transduction pathways during hepatic oncogenesis. *Cancer Lett*. 2016;370(1):1-9.
33. Wang L, Xiao Z, Yue Z, Zhao H, Fan Z, Zhao M, He F, Dai S, Qiu B, Yao J, Lin Q, ***Dong X****, Liu F. Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial. *Sci Rep.* 2016;6:21011.
34. Luan Y[#], Liu Y[#], Lin Q, He F, ***Dong X****, Xiao Z. Serum miRNAs signature plays an important role in keloid disease. *Curr. Mol. Med.* 2016;16(5):504-14. (co-corresponding author)
35. Liu Y, Chen X, Qiang S, Lin Q, He F, ***Dong X****, Xiao Z. Effects of EGF on apoptosis of adipose derived stem cells by regulating miRNA-21. *Wound Medicine* 2016;12:10–14. (co-corresponding author)
36. Pang H, Feng T, Lu H, Meng Q, Chen X, Shen Q, ***Dong X***, Cai L. Efficacy and Safety of Nedaplatin in Advanced Breast Cancer Therapy. *Cancer Invest.* 2016;34(4):167-72.
37. Wang Z, Qu K, Niu W, Lin T, Xu X, Huang Z, Liu S, Liu S, Chang H, Liu Y, ***Dong X***, Liu C, Zhang Y. Glutathione S-transferase P1 gene rs4147581 polymorphism predicts overall survival of patients with hepatocellular carcinoma: evidence from an enlarged study. *Tumour Biol.* 2016;37(1):943-52.
38. Nadolny C, ***Dong X****. Liver Receptor Homolog-1 (LRH-1): A Potential Therapeutic Target for Cancer. *Cancer Biol Ther.* 2015;16(7):997-1004.
39. ***Dong X****, Lin Q, Aihara A, Yu Li, Haung C, Chung W, Tang Q, Chen X, Carlson R, Nadolny C,

Gabriel G, Olsen M, Wands J. Aspartate β-hydroxylase expression promotes a malignant pancreatic cellular phenotype. *Oncotarget* (co-corresponding author) 2015;6(2):1231-48.

40. Zhang K, Zhu S, Liu Y, ***Dong X***, Shi Z, Zhang A, Liu C, Chen L, Wei J, Pu P, Zhang J, Jiang T, Han L, Kang C. ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/β-catenin activity. *Cancer Lett.* 2015;357(1):404-11.
41. Aihara A, Huang C, Olsen M, Lin Q, Chung W, ***Dong X****, Wands J*. A Cell surface β-Hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. *Hepatology* (co-corresponding author) 2014;60(4):1302-13.
42. Lin Q, Aihara A, Chung W, Li Y, Huang Z, Chen X, Weng S, Carlson R, Shaikh Z, Wands J, ***Dong X***. LRH1 promotes pancreatic cancer metastasis. *Cancer Lett.* 2014;350(1-2):15-24.
43. Lin Q, Aihara A, Chung W, Li Y, Huang Z, Chen X, Weng S, Carlson R, Wands J, ***Dong X***. LRH1 as a driving factor in pancreatic cancer growth. *Cancer Lett.* 2014;345:85-90.
44. Zhao Y, Wang H, Li X, Meng Q, Sun L, Pang H, Li H, ***Dong X****, Cai L. Ang II increases cell migration through PI3K/Akt and NF-κB pathways in breast cancer. *J Cell Physiol.* (co-corresponding author) 2014;229(11):1855-62.
45. Bao Z, Yuan X, Duan S, ***Dong X***. Clinical implication of changes in serum adiponectin in patients with hepatogenic diabetes. *Sci Rep.* 2014 Jul 3;4:5560.
46. Li C, Liu M, Yan A, Liu W, Hou J, Cai L, ***Dong X***. ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer. *Tumour Biol.* 2014;35(12):12707-12.
47. Li Z, Fu Y, Li Q, Yan F, Zhao J, ***Dong X***, Zhang Y. Cryoablation plus chemotherapy in colorectal cancer with liver metastases. *Tumor Biol.* 2014;35(11):10841-8.
48. Wang J, Raimondo M, Guha S, Chen J, Diao L, ***Dong X***, Wallace M, Killary A, Frazier M, Woodward T, Wang J, Sen S. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. *J. Cancer* 2014;5(8):696-705.
49. Cao M, Li Y, Lu H, Meng Q, Wang L, Cai L, ***Dong X***. miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells. *J Cancer Res Clin Oncol.* 2014;140(10):1661-70.
50. Gao Y, Wang Y, Sun L, Meng Q, Cai L, ***Dong X***. Expression of TGFβ-1 and EHD1 correlated with survival of non-small cell Lung cancer. *Tumour Biol.* 2014;35(9):9371-80. (co-corresponding author)
51. Yuan K, Liu H, Huang L, Ren X, Liu J, ***Dong X***, Tian W and Jia Y. Rs744166 polymorphism of the STAT3 gene is associated with risk of gastric cancer in a Chinese population. *Biomed Res Int.* 2014;2014:527918.
52. Liu J, Liu H, Zhang T, Ren X, Nadolny C, ***Dong X***, Huang L, Yuan K, Tian W, Jia Y. Serum Helicobacter pylori NapA antibody as a potential biomarker for gastric cancer. *Sci Rep.* 2014;4:4143.
53. Chen X, Li Y, Lin Q, Wang Y, Sun H, Wang J, Cui G, Cai L, ***Dong X***. Tea polyphenols induced apoptosis of breast cancer MCF-7 cells by suppressing the expression of Survivin. *Sci Rep.* 2014;4:4416.
54. Chen X, Sun L, Li Y, Zhang T, Lin Q, Meng Q, Pang H, Zhao Y, Cai L, ***Dong X***. Baseline staging tests based on subtype classification are necessary in the patients with newly diagnosed breast cancer. *J Exp Clin Cancer Res.* 2014;33:28. (co-corresponding author)
55. Chen X, Cong Y, Pan L, Jiang Y, Meng Q, Sun L, Pang H, Zhao Y, ***Dong X****, Cai L. Luminal (Her2 negative) prognostic index and survival of breast cancer patients. *Cancer Epidemiol.*

2014;38(3):286-90. (co-corresponding author)

56. Zhao Y, Lu H, Yan A, Yang Y, Meng Q, Sun L, Pang H, Li C, ***Dong X****, Cai L. ABCC3 as a maker for multidrug resistance in non-small cell lung cancer. *Sci Rep.* 2013;3:3120. (co-corresponding author)
57. Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, ***Dong X****, Cai L. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer. *Cancer Epidemiol.* 2013;37(6):985-92. (co-corresponding author)
58. Javle M, Li Y, Tan D, ***Dong X***, Chang P, Kar S, Li D. Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer. *PLoS One.* 2014;9(1):e85942.
59. Tian W, Jia Y, Yuan K, Huang L, Nadolny C, ***Dong X***, Ren X, Liu J. Serum antibody against Helicobacter pylori FlaA and risk for gastric cancer. *Helicobacter* 2014;19(1):9-16.
60. Huang L, Yuan K, Liu J, Ren X, ***Dong X***, Tian W, Jia Y. Polymorphisms of the TLR4 gene and risk of gastric cancer. *Gene.* 2014;537(1):46-50.
61. Peng X, Chen SF, Du C, Yang P, Liang SX, Zhang G, ***Dong X****. Clinical features and prognostic factors in patients with nasopharyngeal carcinoma relapse after primary treatment. *Head Neck Oncol.* 2013;5(2):21.
62. Liu S, Liang B, Gao H, Zhang F, Wang B, ***Dong X****, Niu J. Integrin αvβ6 as a novel marker for diagnosis and metastatic potential of thyroid carcinoma. *Head Neck Oncol.* 2013;5(1):7.
63. Du C, Yang P, Zhang G, Hong C, Chen J, ***Dong X****. Effect of Arsenic trioxide on EBV LMP1 mediated E-cadherin silencing in nasopharyngeal carcinoma. *Head Neck Oncol.* 2012; 4 (2):55.
64. Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, ***Dong X****. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. *Cancer Lett.* 2013;328(2):318-24.
65. Gu M, ***Dong X****, Zhang X, Wang X, Qi Y, Yu J, Niu W. Strong Association between Two Polymorphisms on 15q25.1 and Lung Cancer Risk: A Meta-analysis. *PLoS ONE* 2012;7(6):e37970. (co-first author)
66. Guo S, Li X, Gao M, Kong H, Li Y, Gu M, ***Dong X****, Niu W. Synergistic Association of PTGS2 and CYP2E1 Genetic Polymorphisms with Lung Cancer Risk in Northeastern Chinese. *PLoS ONE* 7(6): e39814. (co-corresponding author)
67. Bao Z, Yuan X, Wang L, Sun Y, ***Dong X****. The incidence and etiology of community acquired pneumonia in fever outpatients. *Exp Biol Med (Maywood).* 2012;237(11):1256-61. (co-corresponding author)
68. Ao J, Meng J, Zhu L, Nie H, Yang C, Li J, Gu J, Lin Q, Long W, ***Dong X***, Li C. Activation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasion. *Mol Oncol.* 2012;6(5):507-15.
69. Li D, Duell EJ, Yu K, Risch HA, Olson SH, Kooperberg C, Wolpin BM, Jiao L, ***Dong X***, et al. Pathway Analysis of Genome-wide Association Study Data Highlights Pancreatic Development Genes as Susceptibility Factors for Pancreatic Cancer. *Carcinogenesis* 2012;33(7):1384-90.
70. ***Dong X****, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL, Li D. Insulin-like Growth Factor Axis Gene Polymorphisms and Pancreatic Cancer Risk. *Cancer Epidemiol.* 2012; 36(2):206-11. (Corresponding author)
71. ***Dong X****, Li Y, Chang P, Hess KR, Abbruzzese JL, Li D. DNA Mismatch Repair Network Gene Polymorphism as a Susceptible Factor for Pancreatic Cancer. *Mol Carcinog.* 2012; 51(6):491-9. doi: 10.1002/mc.20817. (Corresponding author)

72. Gu M, ***Dong X****, Zhang X, Guo S, Niu W. The CAG repeat polymorphism of androgen receptor gene and prostate cancer: A meta-analysis. *Mol Biol Rep.* 2012; 39(3):2615-24. (co-first author)
73. Gu M, ***Dong X***, Shi L, Shi L, Lin K, Huang X, Chu J. Differences in mtDNA whole sequence between Tibetan and Han population suggesting adaptive selection to high altitude. *Gene.* 2012; 496(1):37-44. Epub 2011 Dec 28.
74. ***Dong X***, Li Y, Chang P, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose Metabolic Gene Variations Modulate the Risk of Pancreatic Cancer. *Cancer Prev. Res.* 2011; 4:758-766.
75. ***Dong X***, Li Y, Hess KR, Abbruzzese JL, Li D. DNA Mismatch Repair Gene Polymorphisms Affect Survival of Pancreatic Cancer. *Oncologist* 2011; 16(1):61-70.
76. ***Dong X***, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer. *Cancer* 2011; 117 (3):480-91.
77. Tang H, ***Dong X***, Hassan MM, Abbruzzese JL, Li D. Body Mass Index and Obesity- and Diabetes-associated Genotypes and Risk for Pancreatic Cancer. *Cancer Epidemiol Biomarkers Prev.* 2011; 20:779-792.
78. ***Dong X***, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like Growth Factor Axis Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer. *Gastroenterology* 2010; 139 (2): 464-473.e3. Epub 2010 Apr 21.
79. Tang H, ***Dong X***, Day RS, Hassan MM, Li D. Antioxidant Genes, Diabetes and Dietary Antioxidants in Association with Risk of Pancreatic Cancer. *Carcinogenesis* 2010; 31(4):607-13.
80. Gu ML, ***Dong XQ***, Zhao J. New insight into the genes susceptible to asthma. *J Asthma.* 2010; 47(2):113-6.
81. Tanaka M, Javle M, ***Dong X***, Eng C, Abbruzzese JL, Li D. Gemcitabine Metabolic and Transporter Gene Polymorphisms Are Associated with Drug Toxicity and Efficacy in Patients with Locally Advanced Pancreatic Cancer. *Cancer* 2010; 116(22):5325-35.
82. ***Dong X,*** Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D. Significant association of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. *J Clin Oncol.* 2009; 27(10):1592-9.
83. ***Dong X***, Zhou G, Zhai Y, Zhang H, Yang H, Zhi L, Zhang X, Chu J, He F. Association of DLC1 gene polymorphism with susceptibility to hepatocellular carcinoma in Chinese hepatitis B virus carriers. *Cancer Epidemiol.* 2009; 33:265-270.
84. Suzuki H, Li Y, ***Dong X***, Hassan MM, Abbruzzese JL, Li D. Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. *Cancer Epidemiol Biomarkers Prev.* 2008; 17(12):3467-73.
85. ***Dong X***, Zhou G, Chu J, He F. An Update on Correlation between Tumor Suppressor Gene PTEN and Human Cancers. *Journal of International Oncology* 2007; 1:1-3.
86. ***Dong X***, Sui G, Ma Y, Feng Z, Guo Z. Toremifene Induced Apoptosis in MCF-7/ADR Cells. *Journal of Practical Oncology* 2003; 17(2): 96-99.
87. Yu L, ***Dong X***, Liu G. Observation and Handling of the Abnormalities in Chemotherapy Patients Using Auto-control and Easy-to-carry infusion pump. *Chinese Nursing Research* 2002; 16 (4):227.

BOOK CHAPTER

1. ***Dong X***. Respect of HGP and Challenges in Post-genomic Era. In New drug discovery in Post-genomic Era. He F, Du S, Sun J, ed., May 2004; 215-220.

MANUSCRIPT UNDER REVIEW

1. Jin X†, Wang D†, Lei M†, Guo Y, Cui Y, Chen F, ***Dong X****, Chen X. TPI1 activates the

PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5. *Cancers.*

2. Han X, Zhu X, Wang Q, Niu Y, Nie C, Wang W, Liu T, Liu C, Zhai J, Wang J, Du X, ***Dong X****, Tian W*, Li X*, Jia Y*. Identification of CD44, CDH6, ITGAV and SERPINE1 as novel EMT markers based on a 12-gene prognostic signature in gastric cancer. *Cancers.*
3. Yuan R#, Zhao H#, Wang Y#, Yang J, Miao D, He W, ***Dong X****, Jia Y*, Zhao W*. SEPTIN9, SDC2, VIM and ACVR1C combinational non-invasion DNA methylation markers for early diagnosis of colorectal cancer based methylated complementarity. *Am J Cancer Res.*

ABSTRACT

1. Aihara A, Huang C, Olsen M, Lin Q, Chung W, Q Tang, ***Dong X****, Wands J*. Expression of beta-hydroxylase alters the hepatocellular carcinoma phenotype. 65th Annual Meeting of the American Association for the Study of Liver Diseases. The Liver Meeting® 2014, November 7–11, 2014, Hynes Convention Center | Boston, MA
2. Huang C, Iwagami Y, Aihara A, Chung W, de la Monte S, Olsen M, Carlson R, Yu T, ***Dong X***, Wands J. Aspartyl-Asparaginyl-β-Hydroxylase (ASPH) is a Therapeutic Target for Cholangiocarcinoma (CCC). 65th Annual Meeting of the American Association for the Study of Liver Diseases. The Liver Meeting® 2014, November 7–11, 2014, Hynes Convention Center | Boston, MA
3. Shroff RT, Javle MM, ***Dong X***, Kumar VS, Krishnan S, Wolff RA, Abbruzzese JL, Li D. The prognostic value of polymorphisms in the insulin-like growth factor receptor (IGFR) pathway in patients with locally advanced pancreatic cancer (LAPC). J Clin Oncol. 27:15s, 2009 (suppl; abstr 4500).
4. Nadolny C, Lin Q, Tang Q, Chung W, Li Y, Chen X, Huang Z, Weng S, Carlson R, Wands J, ***Dong X***. Role of LRH1 in Cancer Metastasis and Pancreatic Cancer Promotion. 2014 AAPS-NERDG Annual Meeting (May 1, 2014 at the Marriot Hotel in Farmington, Connecticut).
5. Margraf A, Tang Q, Lin Q, ***Dong X***. LRH1 as a driving factor for colon cancer development. 2014 Honors Project Program at The University of Rhode Island (May 1, 2014; Kingston, RI)
6. Nadolny C, Lin Q, Li Y, Chen X, Huang Z, ***Dong X***. Oncogenic Potential of LRH1 in Human Pancreatic Cells. 2013 RI Summer Undergraduate Research Fellows Conference (SURF) (August 2, 2013; Kingston, RI).
7. Javle M, ***Dong X***, Tan D, Li Y, Kar SP, Baladandayuthapani V, Weatherly J, Krishnan S, Huang TCJ, Fogelman DR, Abbruzzese JL, Wolff RA, Li D. Transforming growth factor (TGF) β pathway and clinical outcome of pancreatic cancer. AACR 2012 (103rd Annual Meeting; March 31- April 4, 2012; Chicago, IL).
8. ***Dong X***, Li Y, Fisher WE, Chang P, Abbruzzese JL, Li D. Overexpression of NR5A2/LRH1 in Pancreatic Cancer and Possible Association with Clinical Outcome. 6th International Society of Gastroenterological Carcinogenesis (ISGC); January 6-8, 2011; Houston, Texas.
9. ***Dong X***, Li Y, Fisher WE, Chang P, Abbruzzese JL, Li D. Overexpression of NR5A2/LRH1 in Pancreatic Cancer and Possible Association with Clinical Outcome. AACR 2011 (102nd Annual Meeting; April 2-6, 2011; Orlando, Florida).
10. ***Dong X***, Wang H, Li Y, Fisher WE, Chang P, Abbruzzese JL, Li D. Overexpression of NR5A2/LRH1 in Pancreatic Cancer and Possible Association with Clinical Outcome. The University of Texas MD Anderson Cancer Center: Trainee Research Day 2011.
11. ***Dong X***, Chang P, Li Y, Kar SP, Abbruzzese JL, Javle M, Li D. TGFB1 Genetic Variation and

Clinical Outcome of Pancreatic Cancer. 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 12-16, 2011. San Francisco, CA

12. Javle M, Tan D, Li Y, Kar SP, Baladandayuthapani V, ***Dong X***, Weatherly J, Krishnan S, Huang J, Fogelman D, Abbruzzese JL, Wolff RA, Li D. TGFβ pathway and Clinical Outcome of Pancreatic Cancer. 2012 Gastrointestinal Cancers Symposium (January 19-21, 2012. San Francisco, CA)
13. ***Dong X***, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer. *AACR* 2010 (101st Annual Meeting-April 17-21, 2010; Washington, DC).
14. ***Dong X***, Tang H, Li Y, Chang P, Hess KR, Abbruzzese JL, Li D. Glucose metabolism Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer. Trainee Research Day 2010. The University of Texas MD Anderson Cancer Center. Houston, Texas.
15. ***Dong X***, Tang H, Li Y, Chang P, Li D. Polymorphisms of glucose metabolic genes and risk of pancreatic cancer. *AACR* 2009 (100th Annual Meeting-April 18-22, 2009; Denver, CO).
16. Suzuki H, Li Y, ***Dong X***, Hassan MM, Hyodo I, Abbruzzese JL, Li D. Effects of IGF gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. *AACR* 2009 (100th Annual Meeting-April 18-22, 2009; Denver, CO).
17. ***Dong X***, Javle M, Shroff R, Y Li, H Tang, P Chang, Abbruzzese JL, Li D. Significant Effect of IGF Axis Gene Polymorphisms on Clinical Outcome of Pancreatic Cancer. Trainee Research Day 2009. The University of Texas MD Anderson Cancer Center. Houston, Texas.
18. ***Dong X***, Jiao L, Li Y, Evans DB, Abbruzzese JL, Li D. Significant effects of mismatch repair gene polymorphisms on clinical outcome of pancreatic cancer. *AACR* 2008 (99th Annual Meeting-April 12-16, 2008; San Diego, CA).
19. Li D, Suzuki H, ***Dong X***, Okazaki T, Hassan MM, Abbruzzese JL. Insulin-like growth factor gene polymorphisms and risk of pancreatic cancer. *AACR* 2008 (99th Annual Meeting-April 12-16, 2008; San Diego, CA).
20. ***Dong X***, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D. Significant association of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. Trainee Research Day 2008. The University of Texas MD Anderson Cancer Center. Houston, Texas.
21. ***Dong X***, Jiao L, Li Y, Evans DB, Abbruzzese JL, Li D. Significant effects of mismatch repair gene polymorphisms on clinical outcome of pancreatic cancer. The University of Texas MD Anderson Cancer Center 60th Annual Symposium on Cancer Research. 2007. Houston, Texas.

INVITED VIDEO ABSTRACT

1. ***Dong X.*** Insulin-like Growth Factor Axis Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer. Gastroenterology 2010; 139 (2). ***http://www.gastrojournal.org***

NEWS PRESS RELEASE

1. ASCO (American Society of Clinical Oncology), MD Anderson Cancer Center News Press Release "Glitches in DNA Repair Genes Predict Prognosis in Pancreatic Cancer—MD Anderson study identifies gene variants that interact with known factors for the disease" in Mar. 2009.
2. "Genetic Variants Predict Survival in Pancreatic Cancer-Increasing number of mismatch repair gene polymorphisms linked to increased mortality" *HealthDay News, OncoLink* and *ModernMedicine.*

INVITED LECTURES

1. The University of Texas MD Anderson Cancer Center: Grand Rounds Trainee Research Day 2008: "Significant Effects of Mismatch Repair Gene Polymorphisms on Clinical Outcome of Pancreatic Cancer"
2. The University of Alabama at Birmingham 2011: "FA-BRCA-PARP1 Network Genetic Variation Modulates Clinical Outcome in Pancreatic Cancer"
3. The University of Rhode Island 2011: "Genetic alterations in DNA repair pathways and clinical outcome of pancreatic cancer"
4. General Hospital of Tianjin Medical University 05/15/2014: Manuscript Preparation for Scientific Reports
5. Tianjin Medical University Cancer Institute & Hospital 05/16/2014: Aspartate β-Hydroxylase Promotes Cancer Growth and Progression
6. The University of Oklahoma Health Sciences Center Graduate College, Department of Cell Biology/Biochemistry/Pathology seminar series 09/24/2014: Aspartate β-Hydroxylase Is A Potential Therapeutic Target for Pancreatic Cancer
7. Beijing Shijitan Hospital, Capital Medical University (The 9th Affiliated Hospital of Peking University) 10/15/2014: Scientific Manuscript Preparation, Submission and Revision
8. The University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Experimental Therapeutics Research Program 12/11/2014: ASPH is a potential therapeutic target for pancreatic cancer
9. The 7th Annual Meeting of Asia-Pacific Alliance of Liver Diseases (7th APALD), Qingdao, China, September 18-20, 2015: ASPH as a novel therapeutic target for cancer
10. Peking University International Hospital: Distinguished Speaker Seminar 05/02/2017: Therapeutic Target for Retroperitoneal Tumors
11. First Clinical Hospital of Norman Bethune College of Medicine, Jilin University: Distinguished Speaker Seminar 05/03/2017: Early Diagnosis and Targeted Therapy for Pancreatic Cancer
12. The First Affiliated Hospital of Harbin Medical University: Distinguished Speaker Seminar 05/04/2017: Targeted Therapy for Pancreatic Cancer
13. Harbin Medical University Cancer Hospital: Distinguished Speaker Seminar 05/05/2017: Targeted Therapy for Breast Cancer
14. The University of Oklahoma Health Sciences Center SCC Research Seminar Series 06/02/2017: A Novel Therapeutic Target for Pancreatic Cancer
15. The 3rd Chinese Conference on Retroperitoneal Tumors (CCRPTs) 09/06-09/10/2017: **Academic Committee Chair**; Beijing Conference Center
16. The 5th Chinese Forum on Coloproctology Innovation 09/06-09/10/2017: **Academic Committee Chair**; Beijing Conference Center
17. The 4th Chinese Conference on Retroperitoneal Tumors 8/24-8/26/2018: **Academic Committee Chair**; Qingdao Huanghai Hotel, Qingdao, China
18. Peking University International Hospital: Distinguished Speaker Seminar 10/24/2019: Early Diagnosis and Targeted Therapy for Cancer; Beijing, China
19. Fudan University Shanghai Cancer Center: Distinguished Speaker Seminar 10/25/2019: Early Diagnosis and Targeted Therapy for Cancer; Shanghai, China
20. Shanghai Jiaotong University Xinhua Hospital: Workshop 10/26/2019: Early Diagnosis and Targeted Therapy for Cancer; Shanghai, China
21. Shanghai Jiaotong University Ruijin Hospital: Workshop 10/27/2019: Early Diagnosis and Targeted Therapy for Cancer; Shanghai, China
22. Lifespan/Rhode Island Hospital, Brown University - The First Affiliated Hospital, Sun Yat-sen

University Memorandum of Understanding Signing Ceremony 10/28/2019: Guangzhou, Guangdong Province, China

23. The First Affiliated Hospital, University of Science and Technology of China (USTC): Distinguished Speaker Seminar 11/4/2019: Early Diagnosis and Targeted Therapy for Cancer; Hefei, Anhui Province, China
24. iKang Healthcare Group: Conference; Early Diagnosis and Targeted Therapy for Cancer; Beijing, China

POSTER PRESENTATIONS

1. Nadolny C, Lin Q, Li Y, Chen X, Huang Z, ***Dong X***. Oncogenic Potential of LRH1 in Human Pancreatic Cells. 2013 RI Summer Undergraduate Research Fellows Conference (SURF) (August 2, 2013; Kingston, RI).
2. Javle M, ***Dong X***, Tan D, Li Y, Kar SP, Baladandayuthapani V, Weatherly J, Krishnan S, Huang TCJ, Fogelman DR, Abbruzzese JL, Wolff RA, Li D. Transforming growth factor (TGF) β pathway and clinical outcome of pancreatic cancer. *AACR* 2012 (103rd Annual Meeting; March 31- April 4, 2012; Chicago, IL).
3. ***Dong X***, Wang H, Li Y, Fisher WE, Chang P, Abbruzzese JL, Li D. Overexpression of NR5A2/LRH1 in Pancreatic Cancer and Possible Association with Clinical Outcome. The University of Texas MD Anderson Cancer Center: Trainee Research Day 2011.
4. ***Dong X***, Li Y, Wang H, Fisher WE, Chang P, Abbruzzese JL, Li D. Overexpression of NR5A2/LRH1 in Pancreatic Cancer and Possible Association with Clinical Outcome. *AACR* 2011 (102nd Annual Meeting; April 2-6, 2011; Orlando, Florida).
5. ***Dong X***, Li Y, Fisher WE, Chang P, Abbruzzese JL, Li D. Overexpression of NR5A2/LRH1 in Pancreatic Cancer and Possible Association with Clinical Outcome. 6th International Society of Gastroenterological Carcinogenesis (ISGC); January 6-8, 2011; Houston, Texas.
6. ***Dong X***, Chang P, Li Y, Kar SP, Abbruzzese JL, Javle M, Li D. *TGFB1* Genetic Variation and Clinical Outcome of Pancreatic Cancer. 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 12-16, 2011. San Francisco, CA
7. ***Dong X***, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer. AACR. 2010 (101st Annual Meeting-April 17-21, 2010; Washington, DC).
8. ***Dong X***, Tang H, Li Y, Chang P, Hess KR, Abbruzzese JL, Li D. Glucose metabolism Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer. Trainee Research Day 2010. The University of Texas MD Anderson Cancer Center. Houston, Texas.
9. ***Dong X***, Javle M, Shroff R, Y Li, H Tang, P Chang, Abbruzzese JL, Li D. Polymorphisms of IGF Axis Genes and Clinical Outcome of Pancreatic Cancer. Trainee Research Day 2009. The University of Texas MD Anderson Cancer Center. Houston, Texas.
10. ***Dong X***, Tang H, Li Y, Chang P, Li D. Polymorphisms of glucose metabolic genes and risk of pancreatic cancer. AACR 2009 (100th Annual Meeting-April 18-22, 2009; Denver, CO).
11. ***Dong X***, Jiao L, Li Y, Evans DB, Abbruzzese JL, Li D. Significant effects of mismatch repair gene polymorphisms on clinical outcome of pancreatic cancer. AACR. 2008 (99th Annual Meeting-April 12-16, 2008; San Diego, CA).
12. ***Dong X***, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D. Significant association of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. Trainee Research Day 2008. The University of Texas MD Anderson Cancer Center. Houston, Texas.

13. ***Dong X***, Jiao L, Li Y, Evans DB, Abbruzzese JL, Li D. Significant effects of mismatch repair gene polymorphisms on clinical outcome of pancreatic cancer. The University of Texas M.D. Anderson Cancer Center 60th Annual Symposium on Cancer Research. 2007. The University of Texas MD Anderson Cancer Center. Houston, Texas.

GRANT SUPPORT (TOTAL: $ 1,289,250)

1. National CFIDS Foundation Inc. Chronic Fatigue Syndrome/Myalgic Encephalomyelitis CFS/ME NCF Research Grant ($100,000) Dong (Co-I) 05/01/2021-04/30/2023
ASPH-HIF-1α axis as a novel therapeutic target for chronic fatigue syndrome (CFS)

2. The University of Oklahoma Health Sciences Center ($450,000) Dong (PI) 08/01/2014-08/31/2021
Targeted Therapy of Pancreatic Cancer Invasion and Metastasis

3. The University of Oklahoma Health Sciences Center ($120,500) Dong (PI) 08/01/2014-08/31/2021
Equipment & Personnel

4. URI Division of Research & Economic Development and URI Council for Research Proposal Development Grants ($30,000) Dong (PI) 01/01/2013-12/31/2015
LRH-1 Expression and Clinical Outcome of Pancreatic Cancer

5. National Institute for General Medical Sciences (NIGMS), National Institutes of Health (NIH) RI-INBRE Faculty Development Research Project (Grant No.: 8P20GM103430-12; 2P20GM103430) ($383,750) Dong (PI) 07/20/2012-04/30/2015
The Tumorigenicity Potential of LRH1 in Pancreatic Cancer

6. The University of Rhode Island College of Pharmacy ($200,000) Dong (PI) 03/01/2012-07/31/2014
Molecular Mechanisms of Tumorigenesis

7. The University of Texas MD Anderson Cancer Center Khalifa Bin Zayed Al Nahyan Foundation Award ($ 70,000) Dong (PI) 08/13/2010-02/19/2012
The Cross-Talk between NR5A2/LRH1 and NF-κB Pathway in Pancreatic Cancer

8. 2011 AACR-FNAB Fellows Grant for Translational Pancreatic Cancer Research (Grant No.: 11-30-14-DONG) ($35,000) Dong (PI) 07/01/2011-06/30/2013
NR5A2/LRH1 as a Potential Therapeutic Target of Pancreatic Cancer

PENDING

1. Selected on behalf of Brown to submit the one application allowed for the 2022 Mary Kay Foundation Innovative/Translational Cancer Research Grant ($100,000) Dong (PI) 08/01/2022-7/31/2024
2. CEPI Broadening protection against SARS-COV-2 and new broadly protective Betacoronavirus candidate vaccines ($10,730,600) Dong (Co-I) 08/01/2022-7/31/2025

UNIVERSITY TEACHING ROLES

University of Rhode Island

2012 PHC 517 Interactive Learning (IAL) Gastrointestinal and Endocrine Disorders
BPS 442 Pharmacogenetics and Pharmacogenomics
BPS 641 Biochemical Pharmacology
BPS 489 Special Problems (Independent Study)
BPS 589 Special Problems (Independent Study)
BPS 689 Res. In Biomed & Pharm. Sci. (Independent Study)
PHC 599 Master's Thesis Research (Independent Study)
2013 PHC 699 Doctoral Dissertation Research (Independent Study)
PHC 527 Interactive Learning Session V Spring 2013
PHC 517 Interactive Learning (IAL) Gastrointestinal and Endocrine Disorders Fall 2013
BPS 442 Pharmacogenetics and Pharmacogenomics
BPS 451 Techniques in Medicinal Chemistry and Molecular Biology Fall 2013
BPS 497 Special Problems (Independent Study)
BPS 597 Special Problems (Independent Study)
BPS 697 Res. In Biomed & Pharm. Sci. (Independent Study)

PAST AND CURRENT TRAINEES

Scholar	Institution	Program	Duration
Daisy Yan	Dartmouth College	Undergraduate Research Training at URI (The University of Rhode Island)	12/26/2012-01/15/2013
Christina Nadolny	Bryant University	2013 RI Summer Undergraduate Research Fellows (SURF) at URI	05/28/2013-08/02/2013
Qi Tang	URI	Ph.D. of Biomedical and Pharmaceutical Sciences at URI	09/01/2013-08/31/2019
Christina Nadolny	URI	Ph.D. of Biomedical and Pharmaceutical Sciences at URI	09/01/2013-08/31/2019
Alissa Margraf	URI	Undergraduate Research Initiative: Awards for Scholarly, Creative and Artistic Projects at URI	09/01/2013-08/31/2019
Zheping Huang	URI	Ph.D. Postdoctoral Fellow at URI	12/15/2012-12/14/2013
Xuesong Chen	Harbin Medical University	M.D. Visiting Scholar at URI	01/27/2013-01/26/2014
Yu Li	Harbin Center for Disease Control and Prevention	M.D. Visiting Scholar at URI	01/27/2013-01/26/2014
Qinggang Xu	Jiangsu University	Ph.D. Visiting Scholar at The University of Oklahoma Health Sciences Center	02/16/2014-02/16/2015
Fuliang He	Beijing Shijitan Hospital	M.D. Visiting Scholar at The University of Oklahoma Health Sciences Center	10/01/2015-09/30/2016
Yanmei Zhou	Harbin Medical University	M.D. Visiting Scholar at The Liver Research Center of Rhode Island Hospital/Lifespan, Brown University	3/1/2018-2/28/2019
Xuewei Bai	Harbin Medical University	M.D. Visiting Scholar at The Liver Research Center of Rhode Island Hospital/Lifespan, Brown University	10/1/2017-5/31/2019

Dan Liu	Zhengzhou University	M.D. Visiting Scholar at The Liver Research Center of Rhode Island Hospital/Lifespan, Brown University	6/1/2019-8/31/2021
Guangquan Zhang	Harbin Medical University	M.D. Visiting Scholar at The Liver Research Center of Rhode Island Hospital/Lifespan, Brown University	10/1/2019-9/30/2020
Bo Zhai	Harbin Medical University	M.D. Visiting Scholar at The Liver Research Center of Rhode Island Hospital/Lifespan, Brown University	12/1/2019-12/16/2020
Yoshihiro Matsumoto	National University Corporation Kyushu University, Surgery	Associate Professor, Postdoctoral Fellow	04/01/2021
Yuki YOKOTA	Department of Gastroenterological Surgery, Osaka University	Assistant Professor, Postdoctoral Fellow	04/01/2021
Maarouf, Nader	Brown University	Brown University '23 Sc.B. Candidate in Applied Mathematics - Biology	07/01/2021
Hikaru Jett Hayashi	Brown University	Brown University '22 Sc.B. Candidate: Biology (Immunobiology Track)	07/01/2021